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Abstract—A series of impurities, which were all of the same molecular formula, C17H33NO7, were obtained in the process of
voglibose synthesis. After isolation and puriﬁcation, four isomeric cyclitols were completely assigned by 2D NMR experiments. One
of the compounds was established by single-crystal X-ray diﬀraction analysis as 5,6-dideoxy-5-{[2-hydroxy-1-(hydroxy-
methyl)ethyl]amino}-1-C-(methoxycyclohexylmethyl)-D-epi-inositol.
 2004 Elsevier Ltd. All rights reserved.
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1 (voglibose): R1, R2, R3, R4 = H;  
2:     R2, R3, R4 = H; R1 = C6H11CH2– 
3:  R1, R3, R4 = H; R2 = C6H11CH2– 
4:  R1, R2, R4 = H; R3 = C6H11CH2– 
5:
 
 R1, R2, R3 = H; R4 = C6H11CH2– 
Figure 1. Structure of voglibose and byproducts of its synthesis.
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Scheme 1. Synthetic route to voglibose.Voglibose, 5,6-didexoy-5-{[2-hydroxy-1-(hydroxy-
methyl)ethyl]amino}-1-C-(hydroxymethyl)-D-epi-inositol,
has attracted considerable interest due to its wide range
of therapeutic and pharmacological properties, which
include its excellent inhibitory activity against a-gluco-
sidase and its action against hyperglycemia and various
disorders caused by hyperglycemia.1–3 Voglibose has
shown strong anti-obesity and anti-diabetic activity as it
is a new, potent glucosidase inhibitor and is a drug used
for type 2 diabetes in Japan and China.4–10 Therefore,
synthesis and analysis of this compound is of consider-
able interest.11–13 Four new compounds, which arose as
impurities in the synthesis of the target compound were
obtained (see Scheme 1), and their structures were
determined by 2D NMR experiments, and one of them
was conﬁrmed by single-crystal X-ray diﬀraction studies
as 5,6-dideoxy-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]-
amino}-1-C-(methoxycyclohexylmethyl)-D-epi-inositol
(2).
The structure of voglibose had previously been con-
ﬁrmed by NMR data as shown in Figure 1 and in Tables
1–3. By comparing the 13C NMR chemical shift of
voglibose with compound 2, we found only that C-10* Corresponding author. Tel./fax: +86-571-8795-1264; e-mail: cheyjpan@
zju.edu.cn
0008-6215/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.carres.2004.05.025was deshielded from d 65.19 (voglibose) to d 74.28
(compound 2), and the other signals were very similar in
Table 2. 13C NMR spectral data for voglibose and compounds (2–5)
Voglibose
(1)
2 3 4 5
1 76.28 76.18 77.20 76.54 76.21
2 74.10 74.78 82.50 73.49 74.26
3 72.07 72.28 72.31 81.02 71.48
4 73.16 73.31 73.30 72.43 81.62
5 54.46 54.89 54.48 54.97 50.67
6 29.34 29.27 29.73 29.17 29.00
7 56.51 56.98 56.71 56.78 56.47
8 62.25 62.41 62.24 62.02 62.34
9 58.51 58.93 58.62 58.40 59.13
10 65.19 74.28 65.02 65.17 65.17
11 78.17 80.24 78.98 75.79
12 37.41 38.22 38.14 37.77
13 29.79 29.99 29.90 29.65
14 25.64 25.66 25.62 25.58
15 26.48 26.45 26.45 26.42
16 25.64 25.67 25.62 25.58
17 29.79 30.17 29.90 29.65
Table 3. The diﬀerences of voglibose (1) and compounds (2–4) in their
HMBC (carbon) spectral data
Voglibose
(1)
2 3 4 5
1 6b,10 6b,10 6b,10 2,6b,10 2,6b,10
2 3,6b,10 3,6b,10 3,6b,10,11 6b,10 3,6b,10
3 2 2 2,4 2,4,11 2,4,5
4 2,3,6b 2,3,6b 3,6b 6b 3,6b,11
5 6a,6b 6a,6b 6b 6a,6b 6b
10 2 2,6,11 2 2 2
11 10 2 3 4
Table 1. 1H NMR spectral data for voglibose and compounds (2–5)
Voglibose (1) 2 3 4 5
1 –– –– –– –– ––
2 3.25 (1H) 3.56 (1H) 3.18 (1H) 3.38 (1H) 3.37 (1H)
3 3.67 (1H) 3.76 (1H) 3.89 (1H) 3.64 (1H) 3.86 (1H)
4 3.56 (1H) 3.62 (1H) 3.62 (1H) 3.74 (1H) 3.36 (1H)
5 3.23 (1H) 3.32 (1H) 3.35 (1H) 3.37 (1H) 3.55 (1H)
6 a. 1.36 (1H) a. 1.48 (1H) a. 1.51 (1H) a. 1.48 (1H) a. 1.39 (1H)
b. 1.89 (1H) b. 2.00 (1H) b. 1.96 (1H) b. 2.01 (1H) b. 2.00 (1H)
7 2.70 (1H) 2.82 (1H) 2.85 (1H) 2.88 (1H) 2.86 (1H)
8 3.48 (2H) 3.60 (2H) 3.57 (2H) 3.68 (2H) 3.68 (2H)
9 3.51 (2H) 3.61 (2H) 3.61 (2H) 3.71 (2H) 3.71 (2H)
10 3.35 (2H) 3.39 (2H) 3.46 (2H) 3.47 (2H) 3.54 (2H)
11 3.29 (2H) 3.38 (1H) 3.61 (2H) 3.35 (1H)
3.62 (1H) 3.43 (1H)
12 1.57 (1H) 1.64 (1H) 1.63 (1H) 1.67 (1H)
13 0.86 (1H) 0.95 (1H) 0.94 (1H) 0.95 (1H)
1.67 (1H) 1.78 (1H) 1.75 (1H) 1.78 (1H)
14 1.19 (1H) 1.24 (1H) 1.25 (1H) 1.24 (1H)
1.67 (1H) 1.69 (1H) 1.68 (1H) 1.69 (1H)
15 1.12 (1H) 1.18 (1H) 1.17 (1H) 1.24 (1H)
1.59 (1H) 1.66 (1H) 1.63 (1H) 1.69 (1H)
16 1.19 (1H) 1.24 (1H) 1.25 (1H) 1.24 (1H)
1.67 (1H) 1.69 (1H) 1.68 (1H) 1.69 (1H)
17 0.86 (1H) 0.95 (1H) 0.94 (1H) 0.95 (1H)
1.68 (1H) 1.78 (1H) 1.75 (1H) 1.78 (1H)
2028 H. Zhang et al. / Carbohydrate Research 339 (2004) 2027–2030chemical shift (Tables 1–3). These results suggest that in
the voglibose structure only the –OH group at C-10 is
changed into an –OR group as in compound 2. The 1H–
1H COSY spectrum showed connectivities from H-11 to
H-17, and carbon connectivities from C-11 to C-17,
revealing the fact that part of the R-group of compound
2 was a cyclohexylmethyl constituent.
The HMBC spectral data of compound 2 showed that
the carbon signal at d 78.17 (C-11) correlated with the
proton signal at d 3.39 (s), which connected with the
carbon signal at d 74.28 (C-10) in the HMQC data and
showed cross-peaks with the carbon signals at d 76.18
(C-1), at d 74.78 (C-2) and at d 29.27 (C-6). The struc-ture of compound 2 was thus conﬁrmed, as the hydroxyl
H aligned with C-10 that was replaced by the cyclo-
hexylmethyl group in the voglibose framework (Fig. 1).
Thus 2 is determined to be 5,6-dideoxy-5-{[2-hydroxy-1-
(hydroxymethyl)ethyl]amino}-1-C-(methoxycyclohexyl-
methyl)-D-epi-inositol. The structure was conﬁrmed by
the 2D-NMR spectral data shown in Table 2.
A summary of the crystal data, data collection
parameters and reﬁnement results is given in Table 4. As
shown in Figure 2, the molecular structure of compound
2 contains two six-membered rings. Both ring A (from
C-1 to C-6) and ring B (from C-12 to C-18) adopt chair
conformations. The unit –C-10–O-5–C-11–(C-12–C-17)
connected with C-1 by the way of an equatorial bond,
and the angles of O-1–C-1–C-10 show 108.70(13), C-
10–C-1–C-6 show 112.06(12) and C-10–C-1–C-2 show
106.90(12). The C-10–O-5–C-11 was like a bridge that
aligned with ring A and ring B. The 2-hydroxy-1-[(hy-
droxymethyl)ethyl]amino group aligned with C-5 by the
way of an axial bond, and the angles of C-7–N–C-5
Figure 2. SHELXTL-Plus is drawing of the molecule showing atom
numbering. Displacement ellipsoids are drawn at the 50% probability
level.
Table 4. Crystal data, data collection parameters and reﬁnement
results for compound 2
C17H33NO7 Chunk, colorless
M ¼ 363:44 0.56· 0.50· 0.20mm
Monoclinic, P21 Z ¼ 2
a ¼ 4:437ð2ÞA T ¼ 296ð2ÞK
b ¼ 6:853ð1ÞA k ¼ 0:71073A (MoKa)
c ¼ 16:011ð3ÞA l ¼ 0:10mm1
b ¼ 94:88 Dx ¼ 1:309Mgm3
V ¼ 922:4ð3ÞA3 1:28 < h < =28:74
4872 measured reﬂections x scans
4057 unique reﬂections 106 h6 11
3397 with I > 2rðIÞ 86 k6 9
F ð000Þ ¼ 396 216 l6 21
3 standard reﬂections Every 97 reﬂections
Intensity decay: 2.5% 4057 data
Reﬁnement on F 2 306 parameters
R½F 2 > 2ðF 2Þ ¼ 0:036 w ¼ 1=½r2ðF 2o Þ þ ð0:0556PÞ2
wRðF 2Þ ¼ 0:088 Where P ¼ ðF 2o þ 2F 2c Þ=3
Dqmax ¼ 0:21 eA3 Extinction coeﬃcient 0.016(3)
Dqmin ¼ 0:13 eA3 S ¼ 0:97
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C-6, 110.88(13). There was disorder in the C-9 atoms
distributed over two sites with a distribution ratio of
approximately 50:50.
The H-atom on the NH group was reﬁned freely. The
hydroxyl H-atoms were located in diﬀerence Fourier
syntheses but were treated as riding, together with all the
other H-atoms, with O–H¼ 0.82 and C–H¼ 0.97± 0.98
and Uiso ¼ 1:2Ueq or 1:5Ueq of the carrier atom. Inter-
molecular hydrogen bonds O–H  O were the main
contributions to crystal formation. Bond length
2.7271(17)A and bond angle 170.1 was determined for
O-2–H-2  O-3, 2.8116(17)A and 152.5 was for O-4–
H-4  O-2, and 2.870(5)A and 160.0 was for O-70–H-
70  O-2. Meanwhile in the molecule, hydrogen-
bonded O–H  N appeared in the crystal with a bond
length 2.7642(19)A and 144.2.In comparison with the other compounds, the HMBC
data for compound 3 showed a carbon signal at d 80.24
(C-11) that correlated with the proton signal at d 3.18 (d,
J 9.8Hz), which aligned with the carbon signal at d
82.50 (C-2) in the HMQC data and showed cross-peaks
with the carbon signals at d 65.02 (C-10), at d 72.31 (C-
3) and at d 29.73 (C-6).
Thus for compound 3, the unit –C-2–O–C-11– could
be conﬁrmed, and the structure was established as 5,
6-dideoxy-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]-amino}-
2-C-(cyclohexylmethoxyl)-1-C-(hydroxymethyl)-D-epi}-
inositol. Spectral data are provided in Tables 1–3.
The HMBC data of compound 4 is shown in Table 3
wherein the carbon signal at d 78.98 (C-11) correlates
with the proton signal at d 3.64 (m), which in turn is
aligned with the carbon signal at d 81.02 (C-3). The
HMQC data show cross-peaks with the carbon signals
at d 73.49 (C-2) and at d 72.43 (C-4). The unit –C-3–O–
C-11– was conﬁrmed for compound 4, which establishes
the structure as 5,6-dideoxy-5-{[2-hydroxy-1-(hydroxy-
methyl)ethyl]amino}-3-C-(cyclohexylmethoxyl)-1-C-(hy-
droxymethyl)-D-epi-inositol.
The structure for compound 5 was established by the
HMBC spectral data (Tables 1–3) in which the carbon
signal at d 75.79 (C-11) correlated with the proton signal
at d 3.36 (m), which aligned with the carbon signal at d
81.62 (C-4). The HMQC data showed cross-peaks with
the carbon signals at d 74.26 (C-2), at d 71.48 (C-3) and
at d 29.00 (C-6). In compound 5, the unit –C-4–O–C-11–
was conﬁrmed, and the structure was assigned as 5,
6-didexoy-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-
4-C-(cyclohexylmethoxyl)-1-C-(hydroxymethyl)-D-epi-
inositol.1. Experimental
1.1. General methods
The sample mixture, which was obtained in the process
of voglibose synthesis by the reported method11–13 (see
Scheme 1), was ﬁltered, and the ﬁltrate was concentrated
in a vacuum to aﬀord a crude extract (0.589 g) that was
fractionated by silica gel column chromatography using
increasing proportions of MeOH in (Me)2C@O (starting
at 10%) as eluent.
1.2. Isolation and puriﬁcation of compounds 2–5
The fractionated sample was puriﬁed by column chro-
matography, eluting with 3:1 H2O–MeOH through a
column (2 · 100 cm) of Sephadex G-25 (Pharmacia), to
give 55mg of compound 2, 25mg of compound 3, 31mg
of compound 4 and 19mg of compound 5.
Compound 2: colorless plates; mp 182–183 C;
ESIMS: m=z 364 (M+H)þ and HRMS m=z 364.2326
2030 H. Zhang et al. / Carbohydrate Research 339 (2004) 2027–2030(calcd 364.2330) corresponding to the molecular weight
363 and the molecular formula C17H33NO7; for NMR
data, see Tables 1 and 2.
Compound 3: colorless needles; mp 168–171 C;
ESIMS m=z 364 (M+H)þ and HRMS m=z 364.2330
(calcd 364.2330) corresponding to the molecular weight
363 and the molecular formula C17H33NO7; for NMR
data, see Tables 1 and 2.
Compound 4: colorless needles; mp 177–179 C;
ESIMS m=z 364 (M+H)þ and HRMS m=z 364.2325
(calcd 364.2330) corresponding to the molecular weight
363 and the molecular formula C17H33NO7; for NMR
data, see Tables 1 and 2.
Compound 5: colorless needles; mp 162–163 C;
ESIMS m=z 364 (M+H)þ and HRMS m=z 364.2328
(calcd 363.2330) corresponding to the molecular weight
363 and the molecular formula C17H33NO7; for NMR
data, see Tables 1 and 2.
Crystals of compound 2 suitable for X-ray analysis
were obtained by slow evaporation from an aqueous
solution in 1:1 H2O–MeOH at room temperature over
about 15 days.
1.3. NMR methods
1H NMR (500MHz) and 13C NMR (125MHz) spectra
were recorded on a Bruker DMX-500 spectrometer.
Samples were dissolved in D2O, and chemical shifts are
reported in ppm. Coupling constants (J -values) are
given in Hz, and multiplicities are provided by DEPT
(90a and 135a) spectra.
1.4. MS methods
ESIMS spectra were recorded using a Bruker Esquire
3000 plus mass spectrometer operating in the positive-
ion mode. HRMS spectra were recorded using a Bruker
FT ICR APEX II mass spectrometer operating in the
positive-ion SIMS mode.
1.5. X-ray diﬀraction methods
The structure of compound 2 was solved by SHELXS-
97 (Sheldrick, 1990),14 and expanded by Fourier
techniques. The non-hydrogen atoms were reﬁned
anisotropically. Atomic scattering facts used were taken
from International Tables for X-ray Crystallography.151.6. Supplementary material
Crystallographic data for this paper have been deposited
with the Cambridge Crystallographic Data Centre and
assigned the deposition number CCDC 213674. These
data may be obtained of charge from The Director,
CCDC, 12 Union Road, Cambridge CB2 1EZ, UK
(Fax: +44-1223-336-033; e-mail: deposit@ccdc.cam.
ac.uk or http://www.ccdc.cam.ac.uk/).Acknowledgements
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